Irene Min, PhD
Weill Cornell Medical College
Young Investigator Grant

NANETS congratulates Irene Min, PhD of Weill Cornell Medical College as the NANETS 2018 Young Investigator (YI) Award recipient.

Dr. Min received the grant for her proposal Analysis of Immune Environment for Targeting Metastatic Pancreatic Neuroendocrine Tumors. The goal of this study is to elucidate the tumor-immune networks in localized and metastatic pancreatic neuroendocrine tumors (PNETs) and to determine the effect of macrophage inhibitors on enhancing T cell proliferation in metastatic PNET mouse model.

The Young Investigator (YI) Grant is funded by Novartis International AG, a multinational pharmaceutical company based in Basel Switzerland. The $50,000 Young Investigator (YI) Grant is administered over the course of one year. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.

Odette Cancer Center
Sunnybrook Health Sciences Centre
NCIS Grant

NANETS congratulates Julie Hallet, MD, MSc, FRCSC, of Odette Cancer Center, Sunnybrook Health Sciences Centre, as the 2018 NANETS Clinical Investigator Scholarship (NCIS) recipient. The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field. This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors.

The 2018 recipient, Dr. Julie Hallet, received this grant for her proposal An Evaluation of Patient Reported Outcomes, Patterns of Symptoms Severity, and Survival for Neuroendocrine Tumors. The focus of her program in health services population-based research is to examine process, patterns of care, and outcomes for neuroendocrine tumors (NETs) in order to improve care by identifying and establishing enablers to timely diagnosis and effective management.

She has conducted several projects documenting the epidemiology of NETs and exploring possible sources of care and outcome disparities. Using this previous work as background, support from the NCIS grant will allow her to further her research into process of care of NETs.

IPSEN is proud to sponsor the continuation of Edda’s work on behalf of NET patients through this Clinical Investigator Scholarship. IPSEN Biopharmaceuticals supports this research scholarship in the form of a $50,000 grant directed to NANETS to administer over the course of the one year grant period. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.

University of Alabama at Birmingham
School of Medicine
BTSI Grant

NANETS congratulates Renata Jaskula-Sztul, PhD, of the University of Alabama at Birmingham, School of Medicine, as the NANETS 2018 Basic/Translational Science Investigator (BTSI) Award recipient.

Dr. Jaskula-Sztul received this grant for her proposal, Novel Antibody-Drug Conjugate (ADC) for Pancreatic Neuroendocrine Tumor (PanNET) Targeted Therapy. She has published more than 40 papers and, as a co-investigator, she has received funding for five research grants on targeted drug delivery to neuroendocrine tumors.

Dr. Jaskula-Sztul’s current project on testing antibody-drug conjugates as a potential drug for NET will generate new and exciting information that will form the foundation for future grants.

The Basic/Translational Science Investigator (BTSI) Grant is funded by the Neuroendocrine Tumor Research Foundation (NETRF). The $100,000 BTSI Grant is administered over the course of two years. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.

University of California San Francisco
San Francisco Veterans Affairs Medical Center
NTIG Grant

NANETS congratulates Thomas Hope, MD, of the University of California San Francisco and San Francisco Veterans Affairs Medical Center, as the 2018 NANETS' Theragnostics Investigator Grant (NTIG) recipient. The NTIG is intended to push forward the boundaries of molecularly targeted radionuclide therapy and diagnostics for patients with neuroendocrine tumors.

The 2018 recipient, Dr. Thomas Hope, received this grant for his proposal Optimization of Intra-Arterial Y90-DOTATOC PRRT. He will use the funds to continue his work with Y90-DOTATOC using intra-arterial administration, which is an important therapeutic route for peptide receptor radionuclide therapy (PRRT)-Optimization of Intra-Arterial Y90-DOTATOC PRRT. This grant will also provide significant insight into the issues related to receptor saturation, which is not a well-addressed limitation to improving PRRT treatment.

Dr. Hope is an Associate Professor in Residence in the Abdominal Imaging and Nuclear Medicine sections at UCSF and the San Francisco Veterans Affairs Medical Center. He has published 60 peer-reviewed articles, including 21 first author publications.

Advanced Accelerator Applications (AAA) is proud to sponsor this research scholarship in the form of a $100,000 grant directed to NANETS to administer over the course of the two year grant period. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.